<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03885778</url>
  </required_header>
  <id_info>
    <org_study_id>ID-BVCL-402</org_study_id>
    <nct_id>NCT03885778</nct_id>
  </id_info>
  <brief_title>A Food Effect Study of Besifovir in Healthy Subjects</brief_title>
  <official_title>An Open Label, Randomized, 2-sequence, 2-period, Single-dose Cross-over Design Clinical Trial to Evaluate the Food Effect on Pharmacokinetics of BESIVO in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the PK characteristics and the effect of food on the PK in healthy volunteers&#xD;
      who receive Besifovir dipivoxil in fed versus fasted condition&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, 2-sequence, 2-period, single-dose cross-over clinical trial to&#xD;
      investigate the pharmacokinetics incorporating a comparison of fed/fasted pharmacokinetics of&#xD;
      Besifovir dipivoxil in healthy volunteers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 13, 2019</start_date>
  <completion_date type="Actual">February 12, 2019</completion_date>
  <primary_completion_date type="Actual">January 28, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration [Cmax] of Besifovir</measure>
    <time_frame>Up to 24 Hours after study drug administration</time_frame>
    <description>The Cmax is the maximum observed plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve [AUC] of of Besifovir</measure>
    <time_frame>Up to 24 Hours after study drug administration</time_frame>
    <description>Area under the plasma concentration versus time curve for Besifovir</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Besifovir</measure>
    <time_frame>Up to 24 Hours after study drug administration</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to infinite time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the Cmax [Tmax] of Besifovir</measure>
    <time_frame>Up to 24 Hours after study drug administration</time_frame>
    <description>Time to reach the Cmax of Besifovir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life [t1/2]</measure>
    <time_frame>Up to 24 Hours after study drug administration</time_frame>
    <description>apparent terminal half-life of Besifovir</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety of Besifovir: incidence of treatment emergent adverse event [TEAE]'s, abnormalities</measure>
    <time_frame>Up to 14 days after last study drug administration</time_frame>
    <description>Safety of Besifovir administered orally will be assessed by incidence of treatment emergent adverse event [TEAE]'s, abnormalities in vital sign assessments, ECG's, clinical laboratory assessments, and physical exams</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Food Effect</condition>
  <condition>Health Subjects</condition>
  <arm_group>
    <arm_group_label>A-fasted dosing followed by fed dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fasted dosing of Besifovir dipivoxil followed by fed dosing; Dosing in the fasted state followed by fed dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-fed dosing followed by fasted dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fed dosing of Besifovir dipivoxil followed by fasted dosing; Dosing in the fed state followed by fasted dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Besifovir dipivoxil</intervention_name>
    <description>150mg Besifovir dipivoxil, single dose, oral</description>
    <arm_group_label>A-fasted dosing followed by fed dosing</arm_group_label>
    <arm_group_label>B-fed dosing followed by fasted dosing</arm_group_label>
    <other_name>Besivo tab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject who has the ability to comprehend the study objectives, contents and the&#xD;
             property of the study drug before participating in the trial&#xD;
&#xD;
          2. Age of 19 to 50 years and Body Mass Index [BMI] of 18.0 to 27.0 kg/m2&#xD;
&#xD;
          3. Subject with no congenital or chronic disease and no medically symptomatic findings&#xD;
&#xD;
          4. Subject must be healthy on the basis of vital signs, 12-lead ECG, physical examination&#xD;
             and laboratory test performed at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Medical history&#xD;
&#xD;
               -  History of clinically significant of gastrointestinal system, hepatic portal&#xD;
                  system, cardiovascular system, respiratory system, endocrine system,&#xD;
                  renal-urinary system, immunologic system, musculoskeletal system, neurological,&#xD;
                  or psychiatric system, blood tumor, ophthalmology, otolaryngology disorder(as&#xD;
                  determined by the Investigator).&#xD;
&#xD;
               -  Prior history of a gastrointestinal disorder that may affect drug absorption,&#xD;
                  distribution, metabolism and elimination (e.g., Crohn's disease, ulcer or&#xD;
                  surgery, except for simple appendectomy or hernia surgery)&#xD;
&#xD;
          2. Clinical tests&#xD;
&#xD;
               -  Systolic Blood Pressure: lower than 90mmHg or higher than 140mmHg, Diastolic&#xD;
                  Blood Pressure: lower than 60mmHg or higher than 180mmHg&#xD;
&#xD;
               -  Repeated measurement of laboratory value outside the reference range that the&#xD;
                  investigator considers to be of clinical relevance&#xD;
&#xD;
                    1. Aspartate transaminase [AST] or alanine aminotransferase [ALT] &gt; 1.5 x upper&#xD;
                       limit of normal range&#xD;
&#xD;
                    2. Total bilirubin &gt; 1.5 x upper limit of normal range&#xD;
&#xD;
                    3. estimated glomerular filtration rate [eGFR] &lt; 75mL/min/1.73m2 (using Chronic&#xD;
                       Kidney Disease Epidemiology Collaboration [CKD-EPI] equations)&#xD;
&#xD;
                    4. Positive screening on Hepatitis B surface antigen(HBsAg), anti-Hepatitis C&#xD;
                       virus(HCV), anti-Human immunodeficiency virus(HIV) or Syphilis reagin test&#xD;
&#xD;
               -  Subjects with clinically significant abnormalities in 12-lead ECG determined by&#xD;
                  repeated measurement&#xD;
&#xD;
          3. Allergy, hypersensitivity, and drug abuse&#xD;
&#xD;
               -  History of significant hypersensitivity to Besifovir, this drug ingredient or&#xD;
                  other drug (e.g., aspirin, antibiotics)&#xD;
&#xD;
               -  History of clinically significant allergy/hypersensitivity&#xD;
&#xD;
               -  A history of drug abuse (especially, central nervous system agents such as&#xD;
                  sleeping pills, central painkillers, opiates or psychotropic drugs) or the&#xD;
                  presence of positive reactions to drugs that have abuse potential in urine&#xD;
                  screenings for drugs(amphetamines, barbiturates, cocaine, opiates, cannabinoids,&#xD;
                  and benzodiazepines)&#xD;
&#xD;
          4. The contraindication of comedication drugs and diets&#xD;
&#xD;
               -  Subject who has taken drugs for drug metabolizing enzyme induction and inhibition&#xD;
                  within 1 month before the first adminstration&#xD;
&#xD;
               -  Subject who has taken other ethical the count [ETC] drugs (including prescription&#xD;
                  of herbal medicine) within the last 14 days, or over the count [OTC] drugs within&#xD;
                  the last 10 days (as determined by the Investigators)&#xD;
&#xD;
               -  Subject who has taken abnormal meals (eg. ingestion of grapefruit juice, garlic&#xD;
                  extract, broccoli, and kale) which can affect to drug absorption, distribution,&#xD;
                  metabolism, and excretion [ADME] and supplements within 7 days prior to&#xD;
                  administration of trial medication and during the trial&#xD;
&#xD;
               -  Subject who has participated in any other bioequivalence study or clinical trial&#xD;
                  and taken other investigational products within 3 months prior to the first&#xD;
                  adminstration&#xD;
&#xD;
          5. Donation and receipt of blood&#xD;
&#xD;
               -  Subject who had whole blood donation within 2 months prior to administration of&#xD;
                  trial medication&#xD;
&#xD;
               -  Subject who had component blood donation or transfusion within 1 months prior to&#xD;
                  administration of trial medication&#xD;
&#xD;
          6. Pregnant and contraception&#xD;
&#xD;
               -  Pregnant, positive of pregnancy test or breast-feeding women&#xD;
&#xD;
               -  Subjects who do not use medically acceptable contraception during the entire&#xD;
                  period of the trial&#xD;
&#xD;
                    1. Use of intrauterine device&#xD;
&#xD;
                    2. Use of intercourse contraceptive (male or female) and spermicide&#xD;
&#xD;
                    3. Vasectomy&#xD;
&#xD;
                    4. Tubectomy, canal ligation and hysterectomy&#xD;
&#xD;
          7. Other criteria&#xD;
&#xD;
               -  Use of Xanthine (eg. green tea, coffee, black tea, coke, cocoa, chocolate, energy&#xD;
                  drink, and etc.) within 3 days prior to administration of trial medication and&#xD;
                  during the trial&#xD;
&#xD;
               -  Intake of more than 30g of alcohol per day or who can't abstain from alcohol&#xD;
                  during the trial&#xD;
&#xD;
               -  Subjects who can't quit smoking during the trial&#xD;
&#xD;
               -  Subjects who are considered to be unacceptable in this study under the opinion of&#xD;
                  the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jong-Lyul GhimK</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>March 21, 2019</last_update_submitted>
  <last_update_submitted_qc>March 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

